10-Q: Fennec Pharma Reports Q1 2026 Growth, PEDMARK Sales Up 73%

Fennec Pharmaceuticals announced first quarter 2026 results, with PEDMARK net sales reaching $15.1 million, a 73% increase year-over-year, driven by market penetration and sales force expansion.

Summary

• Fennec Pharmaceuticals reported net product sales of $15.1 million for the first quarter of 2026, a significant increase of 73% compared to $8.75 million in the same period of 2025.
• The company experienced a net income of $201,000 for the quarter, a substantial improvement from a net loss of $1,165,000 in the first quarter of 2025.
• Operating expenses increased to $15.2 million from $9.5 million, primarily due to a rise in selling and marketing expenses, while general and administrative expenses decreased.
• Cash and cash equivalents increased to $40.18 million as of March 31, 2026, from $36.79 million at the end of 2025, indicating a healthy liquidity position.
• The company settled its patent litigation with Cipla, with Cipla agreeing not to enter the U.S. market with its generic product until September 1, 2033.
• Fennec is expanding its clinical research, initiating a third institution-led study for PEDMARK in adolescent and young adult (AYA) and adult patients.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive filing, with strong revenue growth, a return to profitability, and a favorable resolution to patent litigation, indicating a strengthening business position.

Positives

• Net product sales increased by 73% to $15.1 million in Q1 2026 compared to $8.75 million in Q1 2025.
• The company achieved net income of $201,000 in Q1 2026, a significant turnaround from a net loss of $1,165,000 in Q1 2025.
• Cash and cash equivalents increased to $40.18 million, providing strong liquidity.
• Selling and marketing expenses increased significantly, reflecting investment in commercialization and sales force expansion, which is showing early positive results.
• General and administrative expenses decreased by $2.68 million due to the conclusion of litigation activities.
• The settlement with Cipla provides extended market exclusivity for PEDMARK in the U.S. until September 1, 2033.
• Four abstracts evaluating PEDMARK were accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
• Initiation of a new investigator-sponsored study evaluating PEDMARK in AYA and adult patients with head and neck and testicular cancers.

Negatives

• Total operating expenses increased by $5.67 million, largely driven by a significant rise in selling and marketing expenses.
• Despite the net income, the company still incurred a loss from operations of $119,000 in Q1 2026.

Risks

• The company's ability to obtain additional financial resources may be necessary to fund its operating plan.
• Future capital requirements are subject to substantial uncertainty and depend on various factors including research and development progress, collaborations, and commercialization activities.
• There is a possibility of being prevented from pursuing product development, manufacturing, or commercialization if product or technologies infringe on third-party patents.
• The company's drug substance requirements to support clinical programs could fluctuate.
• Competitive and technological advances could impact the business.
• The potential need to develop, acquire, or license new technologies and products.
• Changes in regulatory requirements or the timing and outcome of regulatory review processes.
• The Norgine royalty payments are subject to material reduction if an alternative or generic version of PEDMARQSI becomes available in the Territory.
• The company has not yet received any milestone payments from the Norgine agreement.

Future Outlook

The company anticipates that its existing cash and cash equivalents, combined with projected revenues from PEDMARK, will be sufficient to fund its operating plan for at least the next twelve months. The company continues to pursue strategic alternatives, including collaborations, and its future capital requirements are subject to substantial uncertainty.

Management Comments

• We are encouraged by our continued quarter-over-quarter growth and strong start to the year. 2026 is a defining period for Fennec, with growing clinical interest in independently evaluating PEDMARK (sodium thiosulfate injection) across new patient populations and tumor types that reinforces our confidence in its broader potential.
• At the same time, the strategic enhancements we've made to our field force are already sharpening our execution and expanding our reach - in tandem, the positive experiences we're seeing through our Fennec HEARS program are translating into meaningful access and strong conversion rates, resulting in more patients being treated.
• Coupled with our solid financial foundation, we believe we are well-positioned to continue to build momentum and deliver sustained growth throughout 2026.

Industry Context

StockSavvy.ai notes that Fennec Pharmaceuticals' Q1 2026 results reflect a growing trend in the specialty pharmaceutical sector where targeted therapies for rare or specific patient populations are gaining traction. The significant increase in PEDMARK sales, coupled with expanded marketing efforts and ongoing clinical research into new indications, aligns with industry strategies focused on maximizing the value of approved drugs through broader application and market penetration.

Comparison to Industry Standards

• Fennec's Q1 2026 net product sales of $15.1 million represent a 73% year-over-year increase, which is a strong growth rate for a commercial-stage pharmaceutical company, especially for a product targeting a niche indication like pediatric cancer ototoxicity prevention.
• The company's shift from a net loss of $1.165 million in Q1 2025 to a net income of $0.201 million in Q1 2026 indicates a positive trajectory towards profitability, a key benchmark for sustainable growth in the pharmaceutical industry.
• The significant increase in selling and marketing expenses ($11.4 million in Q1 2026 vs. $3.2 million in Q1 2025) reflects a common strategy in the pharmaceutical sector to invest heavily in commercialization efforts post-approval to capture market share, similar to approaches taken by companies like Vertex Pharmaceuticals with its cystic fibrosis treatments or Gilead Sciences with its antiviral therapies during their respective growth phases.
• The settlement with Cipla, securing U.S. market exclusivity until September 1, 2033, is a critical step in protecting revenue streams, a strategy often employed by biopharmaceutical companies to safeguard their intellectual property and market position against generic competition, akin to patent protection strategies seen with blockbuster drugs from companies like Pfizer or Merck.

Legal Proceedings

• Settlement and license agreement with Cipla Limited and Cipla USA, Inc. resolving patent litigation regarding PEDMARK. Cipla will not enter the U.S. market with its generic product until September 1, 2033, or earlier under certain specified circumstances.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, return to profitability, and extended market exclusivity, potentially leading to increased shareholder value.
• Patients: Continued access to PEDMARK for pediatric patients to reduce the risk of ototoxicity associated with cisplatin treatment.
• Healthcare Providers: Ongoing education and support through Fennec HEARS program to facilitate access and utilization of PEDMARK.
• Distributors: Continued sales and distribution of PEDMARK, with four distributors representing over 10% of net sales in Q1 2026.

Next Steps

• Continue to increase market penetration and access for PEDMARK.
• Expand sales organization to enhance coverage of the U.S. market.
• Pursue regulatory registration strategy for PEDMARK in Japan.
• Evaluate partnering or licensing opportunities in Japan.
• Continue to generate data and expand clinical evidence base for PEDMARK, including in AYA and adult populations.
• Launch PEDMARQSI in additional European markets in 2026.
• Participate in upcoming investor conferences to engage with shareholders and potential investors.

Key Dates

Recommendation

The company demonstrates robust revenue growth, a successful transition to profitability, and has secured extended market exclusivity through litigation settlement. The strategic investments in sales and marketing are yielding significant returns, and ongoing clinical research suggests potential for broader market application. These factors, combined with a healthy cash position, present a compelling investment case for sustained growth.

Keywords

Fennec Pharmaceuticals, PEDMARK, PEDMARQSI, Ototoxicity, Cisplatin, Pediatric Cancer, Oncology, FDA Approval, SEC Filing, 10-Q, Financial Results, Pharmaceuticals